Approval · Notice of Compliance 15602 · 2014
RAN-SIMVASTATIN: Notice of Compliance 15602
Issued May 14, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15602
- Date
- May 14, 2014
- Company
- Ranbaxy Pharmaceuticals Canada Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between trwo companies
- Therapeutic class
- Lipid metabolism regulator
- Canadian reference product
- ZOCOR (Merck Frosst Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RAN-SIMVASTATIN | 02329131 | Marketed |
| RAN-SIMVASTATIN | 02329158 | Marketed |
| RAN-SIMVASTATIN | 02329166 | Marketed |
| RAN-SIMVASTATIN | 02329174 | Marketed |
| RAN-SIMVASTATIN | 02329182 | Marketed |
Medicinal ingredients
- SIMVASTATIN 5 MG per TAB
- SIMVASTATIN 10 MG per TAB
- SIMVASTATIN 20 MG per TAB
- SIMVASTATIN 40 MG per TAB
- SIMVASTATIN 80 MG per TAB